1Antman EM, McCabe CH, GurFinkel E, et al. Enoxaparin prevents death and cardiac ischemic events in unstable angina/non-Q-wave myocardial infarction. Results of Thrombolysis In Myocardial Infarction(TIMI) 11B trial. Circulation, 1999,100:1593-1601.
2Cohen M, Demers C, Gurfinkd EP, et al. The Efficacy and Safety of Subcutaneous Enoxaparin in Nen-Q-Wave Coronary Events Study Group. A comparison of low molecular weight heparin with unfractionated heparin for unstable coronary artery disease. N Engl J Med, 1997,337:447-452.
3The thrombolysis in myocardial infarction (TIM1) 11A trial investigators. Dose-ranging trial of enoxaparin for unstable angina:results of TIMI 11A. JACC, 1997,29:1474-1482.
4Collet JP, Montalescot G, Lison L, et al. Percutaneous coronary intervention after subcutaneous enoxaparin pretreatment in patients with unstable angina pectoris. Circulation, 2001,103:658-663.
5Martin JL, Fry ET, Sanderink GJ, et al. Reliable anticoagulatien with enoxaparin in patients undergoing percutaneous coronary intervention:The pharmacokinetics of enoxaparin in PC1 (PEPCI) study. Catheter Cardiovasc Interv, 2004,61 : 163-170.
6Miller L, Gupta A, Bertolet BD. Use of clopidogrel loading,enoxaparin and double-bolus eptifibatide in the setting of early percutaneous coronary intervention for acute coronary syndromes. J Invasive Cardiol, 2002,14:247-250.
7Kereiakes DJ, Grines C, Fry E, et al. Enoxaparin and abciximab adjunctive pharmacotherapy during percutaneous coronary intervention.J Invasive Cardiol, 2001,13:272-278.
8Choussat R, Montalescot G, CoUet JP, et al. A unique, low dose of intravenous enoxaparin in elective percutaneous coronary intervention. J Am Coll Cardiol, 2002,40:1943-1950.
9Bhatt DL, Lee B1, Custerena PJ, et al. Safety of concomitant therapy with eptifibatide and enoxaparin in patients undergoing percutaneuns coronary intervention: results of the Coronary Revascularization Using Integrilin and Single bolus Enoxaparin Study. J Am Coll Cardiol,2003,41:20-25.
10Galeote G, Hussein M, Sobrino N, et al. Use of enoxaparin or unfractionated heparin and abciximab during percutaneous coronary interventions: a randomised pilot study. Rev Esp Cardiol, 2002,55:1261-1266.
